Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients

Many patients with multiple sclerosis (MS) are currently receiving treatment with interferon (IFN)–β. Early identification of nonresponder patients is crucial to try different therapeutic approaches. We investigated various criteria of treatment response to assess which criterion better identifies patients with a poor response.

[1]  L. Greller,et al.  Transcription-Based Prediction of Response to IFNβ Using Supervised Computational Methods , 2004, PLoS biology.

[2]  C. Tornatore,et al.  Identifying and treating patients with suboptimal responses , 2004, Neurology.

[3]  R. Rudick,et al.  Defining interferon β response status in multiple sclerosis patients , 2004 .

[4]  A. Bertolotto,et al.  Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis , 2004, Neurology.

[5]  M. Clanet,et al.  Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis , 2004, Multiple sclerosis.

[6]  E. Hahn,et al.  Long-Term Follow-Up of Childhood-Onset Hypopituitarism in Patients with the PROP-1 Gene Mutation , 2003, Hormone Research in Paediatrics.

[7]  S. Vukusic,et al.  Clinical characteristics of responders to interferon therapy for relapsing MS , 2003, Neurology.

[8]  P. Giral,et al.  Lipoprotein Lipase Activity and Common Gene Variants in Severely Hypertriglyceridemic Patients with and without Diabetes , 2003, Hormone Research in Paediatrics.

[9]  J. Lünemann,et al.  TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis , 2003, The Lancet.

[10]  L. Staudt,et al.  Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. , 2003, Brain : a journal of neurology.

[11]  G. Forster,et al.  Steroid Correlates of Territorial Behavior in Male Jacky Dragons, Amphibolurus muricatus , 2003, Brain, Behavior and Evolution.

[12]  Carlos Nos,et al.  Assessment of different treatment failure criteria in a cohort of relapsing–remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials , 2002, Annals of neurology.

[13]  C. Pozzilli,et al.  Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS , 2001, Neurology.

[14]  G. Coppola,et al.  HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis , 2001, Neurology.

[15]  C Confavreux,et al.  Relapses and progression of disability in multiple sclerosis. , 2000, The New England journal of medicine.

[16]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[17]  F. Heidenreich,et al.  Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS , 2000, Neurology.

[18]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. , 1999, Brain : a journal of neurology.

[19]  D. Paty,et al.  Magnetic resonance imaging results of the PRISMS trial: A randomized, double‐blind, placebo‐controlled study of interferon‐β1a in relapsing‐remitting multiple sclerosis , 1999 .

[20]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.

[21]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[22]  Jeanelle Sheeder,et al.  Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis , 1998 .

[23]  J. Baskerville,et al.  Meta-analysis of the placebo-treated groups in clinical trials of progressive MS , 1996, Neurology.

[24]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[25]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[26]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. , 1991, Brain : a journal of neurology.

[27]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. , 1991, Brain : a journal of neurology.

[28]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. , 1989, Brain : a journal of neurology.

[29]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[30]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .